Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.68 |
| ▸ | KDR | P35968 | 6/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | KIF5B | P33176 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13946642 | 0.93 | EGFR (0.62) | EGFRERBB2KDRFGFR1FLT1 | |
| SCHEMBL2736370 | 0.92 | EGFR (0.56) | EGFRERBB2 | |
| SCHEMBL5505972 | 0.92 | EGFR (0.56) | EGFRERBB2 | |
| SCHEMBL2736391 | 0.86 | EGFR (0.52) | EGFRERBB2 | |
| SCHEMBL5498832 | 0.86 | EGFR (0.52) | EGFRERBB2 | |
| SCHEMBL8304947 | 0.83 | EGFR (0.81) | EGFRERBB2KDRFGFR1FLT1 | |
| SCHEMBL8307435 | 0.83 | EGFR (0.83) | EGFRERBB2KDRFGFR1FLT1 | |
| SCHEMBL8306859 | 0.82 | EGFR (1.00) | EGFRERBB2KDRFGFR1FLT1 | |
| Hydrochloric Acid SCHEMBL8309362 | 0.81 | EGFR (0.98) | EGFRERBB2KDRFGFR1FLT1 | |
| SCHEMBL8307018 | 0.77 | EGFR (0.85) | EGFRERBB2KDRFGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088766-B2 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ERBB2, GRB2, EGFR | EGFR 3/4885ERBB2 1/4885KDR 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.